Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
NCT ID: NCT04753658
Last Updated: 2024-09-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
15 participants
OBSERVATIONAL
2021-03-19
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
NCT03107988
ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma
NCT00533169
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
NCT06333899
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
NCT03834961
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
NCT02637687
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pediatric Neuroblastoma Patients Treated with Lorlatinib
lorlatinib
Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lorlatinib
Oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HCP documentation of at least one tumor assessment of response after patient has had at least one dose of lorlatinib
* Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
0 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, United States
Westmead Hospital
Westmead, New South Wales, Australia
ST0683AU - Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050 Australia, , Australia
Starship Blood and Cancer Centre
Auckland, , New Zealand
Instituto Portugues de Oncologia de Lisboa
Lisbon, , Portugal
Seoul National University Bundang Hospital
Seongnam, , South Korea
Samsung Medical Center
Seoul, , South Korea
Queen Silvia Children's Hospital
Gothenburg, , Sweden
HRH Crown Princess Victoria's Children and Youth Hospital
Linköping, , Sweden
Karolinska Institutet
Stockholm, , Sweden
Norrland University Hospital
Umeå, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B7461036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.